Today: 19 May 2026
British American Tobacco share price ends week higher — buybacks roll on as lawsuit headlines hit the tape
31 January 2026
1 min read

British American Tobacco share price ends week higher — buybacks roll on as lawsuit headlines hit the tape

London, Jan 31, 2026, 07:54 GMT — Market closed

  • British American Tobacco shares ended the day at 4,376p, rising 1.1%.
  • A new buyback filing revealed the cancellation of 131,672 shares repurchased.
  • Investors are focusing on the dividend set for Feb. 4 and the full-year results due Feb. 12.

British American Tobacco (BATS.L) closed Friday 1.1% higher at 4,376 pence, beating the FTSE 100. The tobacco giant’s ongoing buyback program kept investor interest alive.

The market’s closed for the weekend, but BAT is gearing up for a busy stretch. Its next quarterly dividend is set for Feb. 4.

Legal risk has resurfaced. A lawsuit lodged in a Virginia federal court alleges that BAT and one of its units aided North Korea in financing terrorism, reports.

A filing on Friday revealed BAT purchased 131,672 shares from UBS AG London Branch on Jan. 29 at a volume-weighted average price of 4,346.8597 pence. These shares are planned for cancellation. After this move, the company will have 2,177,014,231 shares outstanding, excluding treasury stock.

Tobacco’s outlook has been tangled this week. Altria Group, the U.S. maker of Marlboro, flagged a profit boost in 2026 thanks to a tax rebate called the “double duty drawback.” The company is also leaning on partnerships with firms like KT&G to widen exports. Salvatore Mancuso told Reuters it would be “foolish” to ignore this provision. Reuters

For BAT, the real test ahead is 2026 guidance and cash flow, not just daily buyback figures. Back in December, CEO Tadeu Marroco urged caution for 2026, citing regulatory and competitive headwinds in the U.S. vape market.

The North Korea-related claims add to a well-known history that investors have mostly treated as old news. Back in April 2023, BAT announced it had settled investigations with the U.S. Department of Justice and the Office of Foreign Assets Control, related to past business involving North Korea. The company also said it stopped all North Korea-related activities by September 2017.

That said, the lawsuit could still pack a punch if it uncovers documents that unsettle investors. Timing in legal battles is notoriously unpredictable, and any sign of larger damages—or a wave of similar claims—would challenge the belief that shareholder returns will continue to steal the spotlight.

Traders will be keeping an eye on whether the stock can maintain Friday’s gains when trading restarts on Monday, as well as looking for any company statements beyond the court docket and filings related to the lawsuit.

BAT is set to release its preliminary 2025 results on Feb. 12 at 0700 GMT, followed by a webcast later that morning. This is the next key event to watch.

Stock Market Today

  • Top 5 Blue-Chip Stocks to Boost Portfolio Returns in 2026
    May 19, 2026, 9:58 AM EDT. The Dow Jones Industrial Average briefly surpassed 50,000 in May, highlighting positive momentum supported by its position above key moving averages. Analysts recommend five blue-chip stocks with strong Zacks Rank #2 (Buy) ratings to enhance portfolios in 2026: Cisco Systems (CSCO), Salesforce (CRM), Apple (AAPL), Visa (V), and Chevron (CVX). Cisco benefits from robust AI infrastructure demand and restructuring to focus on growth areas. Salesforce is expanding generative AI offerings through Einstein GPT and strategic investments. These stocks are favored for potential revenue and earnings growth amid evolving technological and economic trends.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

IREN Drops Again After AI Cloud Plans Get Costlier

IREN Drops Again After AI Cloud Plans Get Costlier

18 May 2026
IREN shares dropped 7.2% to $49.15 Monday after the company acquired its marketing partner Awaken, folding the agency into its operations. The decline followed IREN’s $3 billion convertible-note sale last week to fund a major data-center expansion for AI services. Quarterly revenue fell and net loss widened as the company shifts from Bitcoin mining to AI cloud infrastructure.
Wilmar International share price slips to S$3.39 as palm oil turns lower — what to watch before Feb 26 results
Previous Story

Wilmar International share price slips to S$3.39 as palm oil turns lower — what to watch before Feb 26 results

Shopify stock slides nearly 9% as Fed-chair jitters build ahead of Feb. 11 earnings
Next Story

Shopify stock slides nearly 9% as Fed-chair jitters build ahead of Feb. 11 earnings

Go toTop